Blue Water Vaccines, Inc. (NASDAQ: BWV) is engaged as a biopharmaceutical company, which is focused on the research and development of innovative vaccines to address significant health threats around the world. Shares of the vaccine developer are soaring 87% through early trading on Wednesday, August 17, 2022. Over the past three months, Blue Water Vaccines has seen average daily volume of 2.17 million shares. However, volume of 56.38 million shares or dollar volume of around $243.56 million, has already exchanged hands through early trading.
Shares of Blue Water Vaccines are surging after the company announced it will explore developing its own innovative monkeypox vaccine candidate using its norovirus shell and protrusion virus-like particle (VLP) platform. The platform is currently being used to develop other vaccine candidates, such as BWV-101 for influenza, BWV-302 for malaria, BWV-301 for gastroenteritis via norovirus or rotavirus infection and more. As a part of its planned exploration, Blue Water Vaccines will attempt to present monkeypox antigens within its platform to potentially create a vaccine candidate that could protect individuals from the monkeypox virus.
Blue Water Vaccines entered into a global, exclusive licensing agreement with Cincinnati Children’s Hospital to develop novel vaccines using the latter’s virus-like particle vaccine platform. Using norovirus capsid proteins to present foreign antigens, the platform is capable of developing immune enhancement vaccines.
“As monkeypox cases rise around the globe, BWV is committed to exploring the potential of our platform to create a novel monkeypox vaccine candidate,” said Joseph Hernandez, Chairman and Chief Executive Officer of Blue Water Vaccines. “Our VLP platform has previously demonstrated versatility across multiple infectious diseases, and we are excited to initiate this research to understand the potential to create another vaccine to fight this outbreak.”
Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/
The post Blue Water Vaccines (NASDAQ: BWV) Plans Exploration of Virus-Like Particle Platform for Development of Monkeypox Vaccine Candidate appeared first on Spotlight Growth.
